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Reply
We thank Drs. Shelton and Cleland for their interest in our
study (1) and for their thoughtful comments. We agree with
their general statements regarding limitations of antiarrhythmic
agents and the need to develop and rigorously test more
effective rhythm control strategies. However, a few subtle
inaccuracies merit clarification. First, recurrence of atrial fibril-
lation in patients randomized to rhythm control is not synon-
ymous with crossover, as implied. Recurrences (and adverse
effects) are intrinsic to any rhythm control strategy, including
approaches centered on catheter ablation. Rather, in random-
ized trials, crossover refers to a deliberate investigator-approved
change in treatment arm. Second, although large-scale cross-
over in randomized trials remains a vexing problem, its primary
impact on intention-to-treat analyses is to decrease statistical
power. The suggestion that unidirectional crossover (i.e., from
rhythm to rate control but not vice versa) produces less biased
estimates than bidirectional crossover is fallacious. Under certain
conditions, the reverse may be true. Third, insinuating that the
CAFÉ-II (Chronic Atrial Fibrillation and Heart Failure) trial (2),
owever, important, was subject to less confounding than the
F-CHF (Atrial Fibrillation and Congestive Heart Failure) trial
3) is unfounded, if only by virtue of the much larger (N  1,376
s. 61) sample’s enhanced ability to balance unknown or unmea-
ured influential factors, produce normal sample distributions,
ield more precise standard errors, and provide greater statistical
ower.
We share Drs. Shelton and Cleland’s interest in determining
hether more effective and/or less toxic rhythm control strategies
ay outperform rate control. Importantly, this is not analogous to
esting the hypothesis that sinus rhythm is superior to atrial
brillation. Claiming that the statements are equivalent assumes
hat rhythm control is 100% effective, carries no risks or costs, and
as no salutary or harmful effects beyond maintaining sinus
hythm, and that rate control is indistinguishable from no therapy
t all. A few studies support the potential for better rhythm control
trategies to improve outcomes in patients with heart failure
ompared with rate control (4), particularly for “softer” endpoints
1,2) and in selected patient subgroups (5). However, extensive
n-treatment and underlying rhythm analyses from the AF-CHF
rial found no differences in survival and cardiovascular outcomes
hether efficacy was analyzed by initially assigned or time-dependent
odeling of rhythm versus rate control strategies (6). Moreover, to
solate the effect of underlying rhythm irrespective of treatment
trategy, presence of atrial fibrillation, and sinus rhythm were
odeled in a time-dependent fashion. Outcomes were not im-
roved by maintaining sinus rhythm. As such, we challenge the
ssertion that compelling evidence supports the notion that less
armful or toxic rhythm control should outperform rate control.
he issue remains unresolved. Because overwhelming evidence
urrently indicates that rhythm control is not systematically supe-
ior to rate control in patients with atrial fibrillation and symp-
omatic heart failure, the burden of proof will be on future
trategies to demonstrate that this reality has changed.rina Suman-Horduna, MD, MSc
enis Roy, MD
ario Talajic, MD
Paul Khairy, MD, PhD
Montreal Heart Institute
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Niacin Therapy Lives
for Another Day—Maybe?
Being enthusiastic regarding the importance of high-density lipo-
protein cholesterol (HDL-C) and the potential for HDL-C–
raising therapies (1–3), we were disappointed in the outcomes of
the early cholesterol ester transport protein inhibition trial with
torcetrapib (4) as well as the recent AIM-HIGH (Atherothrom-
bosis Intervention in Metabolic Syndrome with Low HDL/High
Triglycerides: Impact on Global Health Outcomes) trial (5) with
extended-release (ER) niacin. Although AIM-HIGH was the
largest and most publicized niacin trial in decades, disappointing
results may partly be due to limitations in the trial, including
higher doses of simvastatin and greater use of ezetimibe (22% vs.
10%) in the statin-only compared with the statin/niacin arm, as
well as the fact that the statin-only group actually received up to
200 mg of immediate-release niacin, and did have an increase in
HDL-C (9.8%) and a reduction in triglycerides (TGs) (8.1%)
and low-density lipoprotein cholesterol (LDL-C) (5.5%) at 2
years. Also, the trial was stopped after only 36 months, which may
have been too short term to notice benefits in patients with
baseline LDL-C levels of only 71 mg/dl, realizing that the original
Lipid Research Clinic–Coronary Prevention Trial with cholesty-
ramine (6) and the 4S (Scandinavian Simvastatin Survival Study)
with simvastatin (7) included patients with markedly higher levels
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May 28, 2013:2194–8of LDL-C (upper 190s mg/dl), and significant benefits were not
noted until well after 3 years in these trials. Nevertheless, despite
including AIM-HIGH in their meta-analysis, Lavigne and Karas’s
analysis (8) of 11 trials in 9,959 subjects in the recent issue of the
Journal still reported reductions in major cardiovascular disease
and coronary heart disease events of 34% (p  0.007) and 25%
p  0.02), respectively, with niacin therapy, potentially partly
alvaging niacin’s reputation as an effective preventive therapy in
ddition to its documented effects in raising HDL-C, and lower-
ng TGs and LDL-C.
However, within days of this Journal publication, we learned
hat the recent Merck trial, HPS2-THRIVE (Heart Protection
tudy2—Treatment of HDL to Reduce Incidence of Vascular
vents) with ER niacin combined with laropiprant, which blocks
he niacin-induced flushing, was stopped. HPS2-THRIVE, the
argest-ever niacin study, enrolling nearly 3 times the number of
atients as in the Journal meta-analysis, failed to show a clinical
enefit for niacin during a mean follow-up of 3.9 years and even
ound a strong signal of potential harm (9). Nevertheless, this trial
ncluded patients regardless of HDL-C levels, and the lack of
enefit (or harm) may not be necessarily due to ER niacin but
ather to laropiprant. We know that laropiprant mainly inhibits
rostaglandin D2 (PGD2) from binding to PGD1 receptors.
lthough the flushing with niacin is mostly mediated by increasing
GD2, this prostaglandin also has important cellular metabolites
hat could provide additional mechanisms of benefit. Specifically,
5-deoxyprostaglandin J2, the main cellular metabolite of PGD2,
s a potent endogenous ligand of peroxisome proliferator-activated
eceptor (PPAR)-gamma, so at least some of niacin’s benefit may
e mediated by stimulation of the PPAR receptor and thus potentially
egated by laropiprant (10).
During the course of a single week, we witnessed a niacin
ip-flop (benefit in the Journal meta-analysis [8] and lack of
enefit and possibly slight harm in the large HPS2-THRIVE trial
9]) that has left clinicians in limbo. Clearly, further subgroup
nalyses of these major ER niacin trials (AIM-HIGH and HPS2-
HRIVE), especially in subgroups most likely to benefit from
iacin therapy (e.g., patients with combined very low levels of
DL-C and elevated TGs) are still needed, which may likely show
enefits in these groups, similar to the benefits of fenofibrate in
hese subgroups, despite the otherwise overall negative results in
he ACCORD (Action to Control Cardiovascular Risk in Diabetes)
ipid trial (11).
The niacin controversy continues, yet we believe that the results
f this Journalmeta-analysis of niacin’s benefits (8) support the fact
hat niacin lives for another day, albeit possibly on life support.
ndeed, niacin is still alive in preventive cardiology, but may need
o be resuscitated in 2013.Carl J. Lavie, MD
ames J. DiNicolantonio, PharmD
ichard V. Milani, MD
ames H. O’Keefe, MD
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